Cigna Corp (CI) Falls 4.03% for January 27

Equities Staff  |

One of the S&P 500’s big losers for Wednesday January 27 was Cigna Corp (CI). The company’s stock fell 4.03% to $129.96 on volume of 2.05 million shares.

The stock opened the day at 135.41 and traded between a low of $129.88 and a high of $135.41. The stock finished the day down $5.46 per share. Cigna Corp has an average daily volume of 1.56 million and a total float of 257.6 million shares. The 50-day SMA for Cigna Corp is $139.07 and its 200-day SMA is $140.48. The high for the stock over the last 52 weeks is $170.68 and the low is $105.23.

Cigna Corp is a health services organization with insurance subsidiaries that are providers of medical, dental, disability, life and accident insurance and related products and services.

Cigna Corp is centered in Bloomfield, CT, and has 37,200 employees. Today’s trading day leaves the company with a market cap of $33.48 billion. The company has a P/S ratio of n/a, P/B ratio of 2.84, and a 27.9.

For a complete fundamental analysis analysis of Cigna Corp, check out’s Stock Valuation Analysis report for CI. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.